Transgene is designing and developing next-generation immunotherapeutics against cancer
Innovative technologies
Push the boundaries of immunotherapy
Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.
Discover our myvac® platform
Discover our invir.IO® platform
TG4050
One patient, one cancer, one vaccine
TG4050 is an individualized neoantigen cancer vaccines from Transgene’s myvac® platform, based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities.
TG4050 is being evaluated in a Phase I/II clinical trial.
TG4050 video
Watch Alessandro Riva presenting first clinical benefits of neoantigen cancer vaccine, TG4050, in head & neck cancer at AACR 2024
Oncolytic viruses
A new generation of products
These innovative multifunctional OVs, from Transgene’s invir.IO® platform, are able to modulate the tumor microenvironment to better attack cancer.
Oncolytic viruses video
TG4001
A therapeutic vaccine in Phase II
TG4001 targets HPV-induced anogenital cancers.
More information
Three therapeutic approaches
Transgene’s immunotherapies harness the mechanisms of the immune response to enable the patient’s body to fight against disease.
- ESMO
ESMO 2024
Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
Donwload Press release (PDF)
Donwload the Poster (PDF) - Presentation
Transgene in a nutshell
Corporate Presentation
Universal Registration Document
Press releases
- September 24, 2024 - Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
- September 14, 2024 - Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment
- September 10, 2024 - Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Last publications
- September 14, 2024 - Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
- September 10, 2024 - TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvionment
- August 27, 2024 - TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment
